Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs JSKN 033 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 20 Jan 2025 New trial record